Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer

Ono, Akira; Naito, Tateaki; Ito, Ichiro; Watanabe, Reiko; Shukuya, Takehito; Kenmotsu, Hirotsugu; Tsuya, Asuka; Nakamura, Yukiko; Murakami, Haruyasu; Kaira, Kyoichi; Takahashi, Toshiaki; Kameya, Toru; Nakajima, Takashi; Endo, Masahiro; Yamamoto, Nobuyuki

doi:10.1016/j.lungcan.2011.12.012

Cited by 25 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prognostic role for tumour markers in SCLC has not been fully established to date; however, some studies have investigated the relationship between prognosis and tumour markers. [34][35][36] Shibayama et al 36 reported on the complementary role of NSE and ProGRP; NSE was found to be superior to ProGRP as a prognostic factor, while ProGRP was more sensitive than NSE regarding the diagnosis of SCLC. Similar to the previous study, the pre-treatment serum NSE level showed a much better correlation with prognosis than ProGRP in our population; however, it was not found to be an independent prognostic factor, when adjusted for stage and PET volumetric parameters.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of fluorine-18 fludeoxyglucose positron emission tomography parameters differs according to primary tumour location in small-cell lung cancer

Nobashi¹,

Koyasu²,

Nakamoto³

et al. 2016

BJR

View full text Add to dashboard Cite

Objective: To investigate the prognostic value of fluorine-18 fludeoxyglucose (FDG) positron emission tomography (PET) parameters for small-cell lung cancer (SCLC), according to the primary tumour location, adjusted by conventional prognostic factors. Methods: From 2008 to 2013, we enrolled consecutive patients with histologically proven SCLC, who had undergone FDG-PET/CT prior to initial therapy. The primary tumour location was categorized into central or peripheral types. PET parameters and clinical variables were evaluated using univariate and multivariate analysis. Results: A total of 69 patients were enrolled in this study; 28 of these patients were categorized as having the central type and 41 patients as having the peripheral type. In univariate analysis, stage, serum neuron-specific enolase, whole-body metabolic tumour volume (WB-MTV) and whole-body total lesion glycolysis (WB-TLG) were found to be significant in both types of patients. In multivariate analysis, the independent prognostic factor was found to be stage in the central type, but WB-MTV and WB-TLG in the peripheral type. Kaplan-Meier analysis demonstrated that patients with peripheral type with limited disease and low WB-MTV or WB-TLG showed significantly better overall survival than all of the other groups (p , 0.0083). Conclusion: The FDG-PET volumetric parameters were demonstrated to be significant and independent prognostic factors in patients with peripheral type of SCLC, while stage was the only independent prognostic factor in patients with central type of SCLC. Advances in knowledge: FDG-PET is a non-invasive method that could potentially be used to estimate the prognosis of patients, especially those with peripheraltype SCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of fluorine-18 fludeoxyglucose positron emission tomography parameters differs according to primary tumour location in small-cell lung cancer

Nobashi¹,

Koyasu²,

Nakamoto³

et al. 2016

BJR

View full text Add to dashboard Cite

show abstract

“…The clinical utility of ProGRP as a biomarker to distinguish SCLC from other lung cancers has been established in a number of studies [12,16,20,21,[39][40][41][42]. In a meta-analysis of 5146 patients enrolled in 11 clinical trials, the sensitivity and specificity of ProGRP in diagnosing SCLC was 0.716 (95% CI 0.688-0.743) and 0.921 (95% CI 0.909-0.932), respectively [40].…”

Section: Discussionmentioning

confidence: 99%

Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China

Korse

Holdenrieder

Zhi

et al. 2015

Clinica Chimica Acta

View full text Add to dashboard Cite

show abstract

“…In two studies[184,187] involving meta-analyses on 5146/6758 patients, 71% and 72% of patients with SCLC had elevated serum-proGRP levels; the specificity was 86% and 92% for SCLC, whereas in one study[184], 92% with other diseases/malignances had low levels. In a number of studies serum-proGRP determinations had greater sensitivity and specificity in SCLC patients than other proposed tumor markers(NSE,CYFRA-21-1)[188]. Changes in serum-proGRP levels show a better correlation with changes in tumor size with treatment in patients with SCLC than changes in serum-NSE and have greater prognostic value than changes in NSE[188].…”

Section: Bn-peptides-bnr: Lung-cancermentioning

confidence: 99%

Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment

Moreno

Ramos-Álvarez

Moody

et al. 2016

Expert Opinion on Therapeutic Targets

102

View full text Add to dashboard Cite

Introduction Despite remarkable advances in tumor treatment, many patients still die from common tumors (breast, prostate, lung, CNS, colon, and pancreas), and thus, new approaches are needed. Many of these tumors synthesize bombesin (Bn)-related peptides and over-express their receptors (BnRs), hence functioning as autocrine-growth-factors. Recent studies support the conclusion that Bn-peptides/BnRs are well-positioned for numerous novel antitumor treatments, including interrupting autocrine-growth via the use of over-expressed receptors for imaging and targeting cytotoxic-compounds, either by direct-coupling or combined with nanoparticle-technology. Areas covered The unique ability of common neoplasms to synthesize, secrete, and show a growth/proliferative/differentiating response due to BnR over-expression, is reviewed, both in general and with regard to the most frequently investigated neoplasms (breast, prostate, lung, and CNS). Particular attention is paid to advances in the recent years. Also considered are the possible therapeutic approaches to the growth/differentiation effect of Bn-peptides, as well as the therapeutic implication of the frequent BnR over-expression for tumor-imaging and/or targeted-delivery. Expert opinion Given that Bn-related-peptides/BnRs are so frequently ectopically-expressed by common tumors, which are often malignant and become refractory to conventional treatments, therapeutic interventions using novel approaches to Bn-peptides and receptors are being explored. Of particular interest is the potential of reproducing BnRs in common tumors, such as the recent success of utilizing overexpression of somatostatin-receptors by neuroendocrine-tumors to provide the most sensitive imaging methods and targeted delivery of cytotoxic-compounds.

show abstract

Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer

Cited by 25 publications

References 27 publications

Prognostic value of fluorine-18 fludeoxyglucose positron emission tomography parameters differs according to primary tumour location in small-cell lung cancer

Prognostic value of fluorine-18 fludeoxyglucose positron emission tomography parameters differs according to primary tumour location in small-cell lung cancer

Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China

Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment

Contact Info

Product

Resources

About